A national non-profit contract research organisation for academic oncology trials
Running an early trial properly requires monitors, data managers, safety reporting and regulatory filings that universities cannot afford from commercial providers. A public not-for-profit would do this work at cost.
A publicly-owned or non-profit CRO providing sponsor-level services (protocol development, regulatory submissions, monitoring, pharmacovigilance, data management, statistics) to academic phase 1 and 2 oncology trials at cost, funded partly by a core grant and partly by fees charged to grants. Academic trials fail or stall for operational, not scientific, reasons; commercial CRO fees consume a large share of academic trial budgets. Precedents include the UK's NIHR clinical research network infrastructure, the EORTC headquarters model for European academic trials, and NCI's CTEP for investigational agents.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
Pages like this
not linked directly; found by shared links- IdeaOpen-source protocol and statistical analysis plan templates with runnable code
Shares EORTC, National Cancer Institute (NIH), Trial design, endpoints and cost.
- IdeaHospital-exemption cell therapies at scale, backed by a shared registry
Shares A public indemnity pool so universities can sponsor first-in-human cancer trials, Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaScale up public drug development that takes academic assets to phase 1
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product, National Cancer Institute (NIH).
- IdeaTwo-year translational fellowships that pay scientists to develop their own discovery
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaA public-benefit phase 1 factory that takes academic discoveries into first-in-human trials
Shares The valley of death between lab and product, National Cancer Institute (NIH).
- IdeaTime to treatment failure and quality of life as co-primary endpoints in non-curative trials
Shares EORTC, Trial design, endpoints and cost.
- IdeaPublish per-patient trial cost benchmarks and target halving them
Shares National Cancer Institute (NIH), Trial design, endpoints and cost.
- InstitutionCancer Prevention and Research Institute of Texas
Shares The valley of death between lab and product, National Cancer Institute (NIH).